Lumerax 80 Tablet contains Artemether 80 mg and Lumefantrine 480 mg, a fixed-dose combination antimalarial medication indicated for the treatment of uncomplicated Plasmodium falciparum malaria. Artemether, a fast-acting artemisinin derivative, rapidly reduces the parasite biomass by generating free radicals that damage the parasite's proteins. Lumefantrine, a longer-acting antimalarial agent, complements Artemether by inhibiting heme polymerization, thereby preventing parasite replication and recrudescence. This synergistic combination ensures rapid clearance of parasitemia and reduces the risk of resistance development. Lumerax 80 is administered orally, with dosing typically based on body weight, and is most effective when taken with fatty meals to enhance absorption. It is contraindicated in patients with known hypersensitivity to either component and should be used cautiously in individuals with cardiac conduction abnormalities due to potential QT interval prolongation. Common adverse effects include headache, dizziness, anorexia, and gastrointestinal disturbances such as nausea and vomiting. Monitoring for signs of hypersensitivity and cardiac arrhythmias is recommended during therapy. Lumerax 80 Tablet is a vital therapeutic option in malaria-endemic regions, offering effective and well-tolerated treatment for acute uncomplicated falciparum malaria.